- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Zai Lab Ltd (ZLAB)
Zai Lab Ltd stock price live, this page displays NASDAQ ZLAB stock exchange data. View the ZLAB premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Zai Lab Ltd real time stock price chart below.
What Is the Zai Lab Ltd Stock Price Today?
The Zai Lab Ltd stock price today is 23.32.
What Is the Stock Symbol for Zai Lab Ltd?
The stock symbol for Zai Lab Ltd is "ZLAB."
What Stock Exchange Does Zai Lab Ltd Trade On?
Zai Lab Ltd is listed and trades on the NASDAQ stock exchange.
Is Zai Lab Ltd a Good Stock to Buy?
Determining whether Zai Lab Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ZLAB quote. (ISIN: US98887Q1040)
What Is the Zai Lab Ltd Stock Price Today?
The Zai Lab Ltd stock price today is 23.32.
What Is the Stock Symbol for Zai Lab Ltd?
The stock symbol for Zai Lab Ltd is "ZLAB."
What Stock Exchange Does Zai Lab Ltd Trade On?
Zai Lab Ltd is listed and trades on the NASDAQ stock exchange.
Is Zai Lab Ltd a Good Stock to Buy?
Determining whether Zai Lab Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ZLAB quote. (ISIN: US98887Q1040)
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
21.58
24.07
52 wk Range
15.96
36.77
Unusual trading volume
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
21.5824.07
52 wk Range
15.9636.77
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ZLAB Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
33.52
Upside
+43.72%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in overbought territory
Form 144 Zai Lab Ltd For: 30 June- Investing.com
Form 8K ZAI LAB LIMITED For: 6 August- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
11 Buy
1 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 33.52
(+43.72% Upside)
Zai Lab Ltd Earnings Call Summary for Q2/2026
- Zai Lab posted Q2 adjusted EPS of -$0.05, beating estimates of -$0.60 by 91.67%; revenue reached $106.3M vs. $104.34M forecast.
- Net product revenue rose 11% sequentially to $105.8M; company ended quarter with $717.5M cash and maintains commercial profitability.
- Management expects revenue stabilization in H2 2026 and meaningful growth in 2027, with first U.S. regulatory submission planned for 2027.
- Zoci ADC advances to global pivotal trials; Phase III data expected at ESMO October 2026 with ~60 patients, targeting 80% response rate.
- ZL-1503 first-in-human data due H2 2026; ZL-1311 IND submission targeted by year-end; operating expenses to remain stable through 2026.
Last Updated: 08/06/2026, 08:52 PM
Read Full TranscriptEarnings
Latest Release
Aug 06, 2026
EPS / Forecast
-0.05 / -0.60
Revenue / Forecast
106.3M / 104.34M
Compare ZLAB to Peers and Sector
Metrics to compare | ZLAB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipZLABPeersSector | |
|---|---|---|---|---|
P/E Ratio | −13.9x | −3.2x | −0.4x | |
PEG Ratio | −0.86 | −0.06 | 0.00 | |
Price/Book | 4.3x | 5.4x | 2.6x | |
Price / LTM Sales | 5.8x | 11.8x | 3.1x | |
Upside (Analyst Target) | 21.2% | 140.2% | 48.8% | |
Fair Value Upside | Unlock | 3.9% | 5.7% | Unlock |
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Zai Lab (ZLAB) Stock Price Today?
The Zai Lab stock price today is 23.32 USD.
What Stock Exchange Does Zai Lab Trade On?
Zai Lab is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Zai Lab?
The stock symbol for Zai Lab is "ZLAB."
What Is the Zai Lab Market Cap?
As of today, Zai Lab market cap is 2.62B USD.
What Is Zai Lab's Earnings Per Share (TTM)?
The Zai Lab EPS (TTM) is -1.70.
When Is the Next Zai Lab Earnings Date?
Zai Lab will release its next earnings report on Nov 10, 2026.
From a Technical Analysis Perspective, Is ZLAB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Zai Lab Stock Split?
Zai Lab has split 0 times.
How Many Employees Does Zai Lab Have?
Zai Lab has 1784 employees.
What is the current trading status of Zai Lab (ZLAB)?
As of Aug 09, 2026, Zai Lab (ZLAB) is trading at a price of 23.32 USD, with a previous close of 20.88 USD. The stock has fluctuated within a day range of 21.58 USD to 24.07 USD, while its 52-week range spans from 15.96 USD to 36.77 USD.
What Is Zai Lab (ZLAB) Price Target According to Analysts?
The average 12-month price target for Zai Lab is 33.52 USD, with a high estimate of 52 USD and a low estimate of 24.25 USD. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +43.72% Upside potential.
What Is the ZLAB Premarket Price?
ZLAB's last pre-market stock price is 21.80 USD. The pre-market share volume is 15,210.00, and the stock has decreased by 0.92, or 4.41%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.